14 completed, 7 recruiting, 7 unknown, 3 active not recruiting. 15 Phase 2, 10 Phase 3, 4 Phase 1, 2 Not applicable, 1 Phase 4.
Follow Anthracyclines: new trials by email Literature Review of Anthracyclines trials Research Report on Anthracyclines
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Study of SA+X in the Treatment of Newly Diagnosed AML Anthracycline, Ivosidenib, Gilteritinib - Acute Myeloid Leukemia | Phase 2 | Recruiting | Ruijin Hospital | 205 | 2026-05-01 | 2026-07-30 |
| Efficacy of Hypomethylating Agents vs. Intensive Chemotherapy in Acute Myeloid Leukemia Using 5hmC as a Blood-Based Minimal Residual Disease Marker 5hmC Biomarker, Venetoclax, Decitabine 20 mg/m²/day for 5 days - Acute Myeloid Leukemia (AML), Acute Myeloid Leukaemia (AML) | Phase 2 | Recruiting | The Methodist Hospital Research Institute | 112 | 2026-04-09 | 2026-10-08 |
| Chemotherapy With or Without Adebrelimab and T-DXh as Neoadjuvant Therapy for HR+/HER2 Low Early Stage Breast Cancer SHR-A1811, Adebrelimab (PD-L1 inhibitor), Taxane Chemotherapy - Breast Cancer Early Stage Breast Cancer (Stage 1-3), HR Positive/HER2 Low Breast Cancer | Phase 2 | Not yet recruiting | Cancer Institute and Hospital, Chinese Academy of Medical Sciences | 249 | 2026-02-15 | 2026-01-05 |
| Posaconazole Plus PD-1 Inhibitors and Chemotherapy vs PD-1 Inhibitors and Chemotherapy in Neoadjuvant Therapy for Triple Negative Breast Cancer Posaconazole, Nab-paclitaxel, Carboplatin - Breast Cancer | Phase 2 | Recruiting | Shandong Cancer Hospital and Institute | 72 | 2025-05-01 | 2026-02-25 |
| Role of Sodium-glucose Linked Transporter 2 (SGLT2) and Its Inhibitor Over CARdiotoxicity Induced by Anthracyclines and Breast Cancer Tumorigenesis SCARA-B Anthracycline - Breast Neoplasms | Recruiting | Centre Paul Strauss | 50 | 2025-02-17 | 2026-02-04 | |
| Studying the Senescent T Cell Features and Its Relationship with the Chemotherapy Efficacy in Young TNBC docetaxel, anthracycline, cyclophosphamide - T-Cell Dysfunction, Chemotherapy Effect | Not yet recruiting | The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School | 30 | 2025-01-01 | 2024-11-12 | |
| Organoid-based Functional Precision Therapy for Advanced Breast Cancer Organoid-guided treatment, Taxane, Capecitabine - HER2-negative Breast Cancer, Advanced Breast Cancer | Phase 2 | Recruiting | Guangdong Provincial People's Hospital | 252 | 2024-10-01 | 2024-11-25 |
| A Study of Tislelizumab Combined With TAC Regimen as Neoadjuvant Therapy for TNBC Nab paclitaxel/Carboplatin, anthracyclines,Tislelizumab - Breast Cancer (Triple Negative Breast Cancer (TNBC)), Chemeotherapy | Phase 2 | Completed | Daping Hospital and the Research Institute of Surgery of the Third Military Medical University | 36 | 2024-10-01 | 2026-09-18 |
| Randomized Study of ABC-14 Regimen Compared With "3+7" Standard Induction Therapy or AB-14 for ND AML Chidamide, Venetoclax, azacitidine - Acute Myeloid Leukemia | Phase 2 | Recruiting | Guangdong Provincial People's Hospital | 240 | 2024-08-21 | 2025-11-17 |
| Predictive Biomarkers of Response to Checkpoint Inhibitors in Triple Negative Breast Cancer: a Multiomics Platform Whole Genome Sequencing, RNA-Sequencing, Microbiome analysis - Triple Negative Breast Cancer | Recruiting | Vall d'Hebron Institute of Oncology | 100 | 2023-01-13 | 2023-06-23 | |
| Pulsed Electromagnetic Fields (PEMFs) - A Highly Selective Breast CAncer Treatment pLatform (PASCAL) Pulsed electromagnetic fields (PEMFs), Device: Pulsed electromagnetic fields (PEMFs); Drug: Anthracycline OR Taxane - Breast Cancer | Phase 1 | Completed | National University Hospital, Singapore | 14 | 2022-12-30 | 2026-03-13 |
| Entospletinib Plus Intensive Induction/Consolidation Chemotherapy in Newly Diagnosed NPM1-mutated AML Entospletinib, Placebo, Cytarabine - Nucleophosmin 1-mutated Acute Myeloid Leukemia | Phase 3 | Terminated | Kronos Bio | 15 | 2021-11-24 | 2024-01-10 |
| Effect of Anthracyclines and Cyclophosphamide on Cardiovascular Responses Physical Characteristics, Muscular Sympathetic Nervous Activity, Cardiac Function - Cardiotoxicity, Cardiovascular Disease | Not applicable | Completed | University of Sao Paulo General Hospital | 15 | 2020-08-03 | 2025-04-03 |
| AT Versus TP as Neoadjuvant Chemotherapy in Patients With HER2-negative Early Breast Cancer AT regimen, TP regimen - HER2-negative Breast Cancer | Phase 2 | Unknown | Sichuan Provincial People's Hospital | 100 | 2020-08-01 | 2020-08-05 |
| NordicTrip, a Translational Study of Preoperative Chemotherapy in TNBC epirubicin, cyclophosphamide, paclitaxel, carboplatin, pembrolizumab, epirubicin, cyclophosphamide, capecitabine, paclitaxel, carboplatin, pembrolizumab - Breast Cancer, Triple Negative Breast Neoplasms | Phase 3 | Active not recruiting | Lund University Hospital | 325 | 2019-12-20 | 2025-09-12 |
| Study of Nivolumab Versus Placebo in Combination With Neoadjuvant Chemotherapy and Adjuvant Endocrine Therapy in Participants With High-risk, Estrogen Receptor-Positive (ER+), Human Epidermal Growth Factor Receptor 2-Negative (HER2-) Primary Breast Cancer nivolumab, paclitaxel (PTX), nivolumab placebo - Breast Cancer | Phase 3 | Completed | Bristol-Myers Squibb | 521 | 2019-11-18 | 2025-01-08 |
| HDM201 Added to CT in R/R or Newly Diagnosed AML HDM201, cytarabine, anthracycline - Leukemia, Myeloid, Acute | Phase 1 / Phase 2 | Withdrawn | Novartis Pharmaceuticals | 2019-11-15 | 2020-01-09 | |
| Xenotransplantation of Primary Cancer Samples in Zebrafish Embryos Fluorouracil, Lederfolin, Oxaliplatin - Liver Cancer, Pancreatic Cancer | Unknown | University of Pisa | 120 | 2018-06-01 | 2018-09-12 | |
| Study to Assess the Safety and Efficacy of Midostaurin (PKC412) in Combination With Standard Chemotherapy During Induction and Consolidation Followed by 12 Months of Maintenance Monotherapy in Patients With Newly-diagnosed FMS-like Tyrosine 3 (FLT3) Kinase Receptor-mutated Acute Myeloid Leukemia. Midostaurin, Cytarabine, anthracycline ((daunorubicin or idarubicin): Induction Phase only - Acute Myeloid Leukemia | Phase 3 | Completed | Novartis Pharmaceuticals | 301 | 2018-02-13 | 2024-02-29 |
| Early Detection of Cardiomyopathy by Speckle Echo, High Sensitive Troponin and Cardiac Ryanodine Receptors Chemotherapy, Cancer, Anthracyclines - Chemotherapy Effect | Unknown | Assiut University | 50 | 2018-01-01 | 2017-12-21 |
Showing 20 of 37. Sign in to see all of them.
Breast Neoplasms (17) · Leukemia, Myeloid, Acute (8) · Triple Negative Breast Neoplasms (5) · Cardiotoxicity (3) · Leukemia (3) · Cardiovascular Diseases (2) · Myelodysplastic Syndromes (2) · Anemia, Refractory, with Excess of Blasts (1) · Biliary Tract Neoplasms (1) · Colonic Neoplasms (1) · Esophageal Neoplasms (1) · Gallbladder Neoplasms (1) · Leukemia, Myeloid (1) · Leukemia, Myelomonocytic, Chronic (1) · Liver Neoplasms (1)
Guangdong Provincial People's Hospital (2) · Novartis Pharmaceuticals (2) · Ruijin Hospital (2) · Assiut University (1) · AstraZeneca (1) · Bristol-Myers Squibb (1) · Cancer Institute and Hospital, Chinese Academy of Medical Sciences (1) · Celgene (1) · Centre Paul Strauss (1) · Cephalon, Inc. (1) · Daping Hospital and the Research Institute of Surgery of the Third Military Medical University (1) · Gruppo Italiano Malattie EMatologiche dell'Adulto (1) · Hospital Israelita Albert Einstein (1) · Institut Paoli-Calmettes (1) · Kronos Bio (1)
China (11) · France (9) · Spain (7) · Italy (6) · United States (6) · Germany (5) · Brazil (4) · Czechia (4) · Hungary (3) · Netherlands (3) · Poland (3) · Sweden (3) · Australia (2) · Austria (2) · Belgium (2)
CL Beach (1) · Carlos E Negrao, PhD (1) · Christian Straka, Prof. Dr. (1) · Dirk Reinhardt, Prof. Dr. med. (1) · Fabio P Santos, MD (1) · Franco Mandelli, Prof. (1) · J.A. Gietema, MD, PhD (1) · Jianyu Weng (1) · Judith Balmana (1)
PMID 18083847, PMID 18182574, PMID 19230772, PMID 20026804, PMID 20136825, PMID 20394651, PMID 20451404, PMID 21480469, PMID 23585522, PMID 23704089, PMID 26814618, PMID 26919165, PMID 27269945, PMID 27662018, PMID 28660778, PMID 32067679, PMID 32183229, PMID 32278621, PMID 32450725, PMID 34048072, PMID 34439284, PMID 37581981, PMID 38913933, PMID 39838118, PMID 40069763, PMID 40803346, PMID 41366419
2008 (1), 2015 (1), 2016 (1), 2018 (1)